Abstract CN95
Background
Radiation cystitis (RC) is a common side-effect of pelvic radiation, which could severely impair patients' quality of life. Platelet-to-albumin ratio (PAR) is a new systemic inflammatory indicator associated with many inflammatory diseases. This study aimed to explore whether PAR could be used as an effective parameter for predicting the RC for local advanced cervical cancer (LACC) treated with radiotherapy.
Methods
319 LACC patients at Fujian Cancer Hospital were enrolled between December 2018 and January 2021. All patients received radiotherapy with or without chemotherapy. Clinical parameters were retrospectively analyzed. Logistic analyses were used to identify the risk factors for RC. Risk factors in univariate analysis (p<0.05) were put in a backward and stepwise regression to construct two nomograms-one with primary significant factors and the other with extra inflammatory biomarkers. A DeLong test was applied to compare the prediction abilities of two nomograms. The stability and credibility of the nomogram with inflammatory biomarkers were assessed by five-fold validation, calibration curves, and decision curve analysis (DCA).
Results
Univariate analysis showed age, tumor size, stage, total radiation dose, pelvic radiation dose, systemic immune-inflammation index(SII), platelet-to-lymphocyte ratio (PLR), and PAR were significantly associated with RC (all p < 0.05). Multivariate analyses indicated age, tumor size, stage, total radiation dose, and PAR were independent factors (all p < 0.05). Then, the area under curve (AUC) value of the nomogramSII+PAR was 0.774 compared to that of the baseline nomogram (AUC = 0.726) (P Delong = 0.02), indicating the great discriminative power of the nomogramSII+PAR and enhancing the critical roles of SII and PAR in predicting RC. Also, the five-cross validation validated the stability of the nomogramSII+PAR. Moreover, the calibration curve and DCA exhibited the nomograms' good prediction consistency and clinical practicability.
Conclusions
PAR and SII could be valued for cervical cancer patients with radiation therapy to stratify patients who require extra intervention to prevent bladder radiation damage and improve patients' quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian, Province, China(Grant NO. 2022ZQNZD008).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
CN58 - Canadian resources and strategies to build global oncology nursing excellence
Presenter: Gayatre Maharaj
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN62 - Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study on 18877 patients
Presenter: Yingxue Liu
Session: EONS Poster Display session
Resources:
Abstract
CN63 - Quality of life among parents of children with cancer
Presenter: Abeer Hussain
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN74 - Exploring the correlation between spiritual health, quality of survival, and meaning of life among breast cancer chemotherapy patients
Presenter: Fang Zhao
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN75 - Telehealth interventions and functional outcomes in breast cancer rehabilitation: A systematic review
Presenter: Marco Invernizzi
Session: EONS Poster Display session
Resources:
Abstract
CN76 - A study of sexual dysfunction in Moroccan female survivors of gynaecological cancer: A prospective study about 220 patients
Presenter: Chadia Ezzouitina
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN77 - ‘Eating with others’: Planning, developing and testing a self-management intervention to promote social eating for patients living with and beyond head and neck cancer
Presenter: Mark Dornan
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN79 - Quality-of-Life (QoL) data published by clinical trials supporting drug approvals for renal cell carcinoma (RCC)
Presenter: Rowanne Seadon
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN80 - Why do some patients undergoing laryngectomy for head and neck cancer opt to not reacquire their voice?
Presenter: Miyoko Iwai
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN81 - How to use a theoretical framework to inform intervention development in a breast cancer study?
Presenter: Sek Ying Chair
Session: EONS Poster Display session
Resources:
Abstract
Slides